Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.

@article{Calvo2001FixedHD,
  title={Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study.},
  author={Emiliano Calvo and J. C. Gal{\'a}n Cort{\'e}s and Javier Saiz Rodr{\'i}guez and M Sureda and C. Beltran and J. C. Zornoza Rebollo and Rafael Mart{\'i}nez-Monge and Jos{\'e} Mar{\'i}a Berian and Jokin de Irala and Antonio Brugarolas},
  journal={Cancer},
  year={2001},
  volume={92 9},
  pages={2435-43}
}
BACKGROUND Using a fixed higher-dose schedule, the efficacy and toxicity of suramin plus hydrocortisone were assessed in patients with metastatic hormone-refractory prostate carcinoma (HRPC). METHODS Fifty consecutive patients with HRPC (including those in whom hormonotherapy was withdrawn) and an Eastern Cooperative Oncology Group performance status of 0… CONTINUE READING